News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

AI Can Now Create Customizable Recipes – Here’s How A Robotic Food Automation Company Has Been Using AI To Become An Industry Leader

Blendid

By Faith Ashmore, Benzinga Interested in investing in Blendid’s campaign? Click here to get started! Artificial Intelligence (AI) technology is quickly proving to be a driver of innovation and efficiency and is fast becoming a normal part of life. In November 2022, tech and news outlet CNET started using AI to write financial articles. The articles were so well-written that the vast majority of the public didn’t realize until a tweet went viral. AI technology is rapidly expanding, and some companies like Blendid have looked to ensure they are ahead of the curve, having made early deployments of AI in their solutions. Whether for restaurant owners or at-home cooks, finding or creating the perfect recipe is a big undertaking. Not only do they have to craft a perfect blend of flavors, but they also have to figure out what they and their customers enjoy. Now imagine they are able to find the best recipes possible for their needs, but they didn’t have to do any of the hard work of producing them. Blendid is looking to revolutionize the game by doing just that, leveraging AI to produce better solutions. The company uses AI technology to create the most appealing recipes for its consumers. Blendid is a robotic and AI-enabled food automation solution company; it currently operates fully autonomous robotic kiosks for smoothies. By using consumer data from purchase behavior, ratings and reviews, and questionnaires, Blendid’s AI system is able to create the best recipes to put on a menu for a particular location. One of the company's best-selling drinks, Sunrise.ai, was crafted completely by AI! Blendid has even gone one step further and is developing a feature to use AI to create customized individual recipes. While this feature is currently only available at the lab, the company is seeing incredible feedback from test subjects and is looking forward to bringing it to the public in the near future. This feature could be especially groundbreaking because it will allow the robot-automated kiosks to create curated recipes for consumers that appeal to their taste preferences while taking into account any allergies and dietary restrictions. In the future, Blendid plans to align its AI-driven recipes with consumers’ personal microbiomes, satisfying both the gut and their taste palate. Blendid reports that its technology-driven model is performing extremely well. In combination with kiosks that can operate 24/7, consumers have access to healthy and personalized food around the clock while the company is able to maintain low operational costs and high margins. Blendid kiosks operate in universities, travel centers, retail stores, and hospitals across the country. The company most recently saw a 267% year-over-year revenue increase. Blendid is currently hosting a raise to expand its concept further. The company is currently working on expanding to a dozen additional geographies in the near future and has 500+ kiosks in contract. Previously, they raised more than $26 million. Interested in investing and being a part of their growth story? Click here to read more about Blendid’s raise and how to invest! This article was originally published on Benzinga here. Sunnyvale-based Blendid is revolutionizing the future of food service with its proprietary food automation platform (foodOS™), which efficiently and safely prepares and serves a range of healthy, fresh, and delicious food. A pioneer of the future of food service, Blendid's first concept in the market is an autonomous, contactless kiosk that uses robotics, machine vision, artificial intelligence, and healthy ingredients to create delicious smoothies that are customized to meet the unique health and dietary preferences of each consumer. Founded in 2015 by seasoned Silicon Valley entrepreneurs Vipin Jain, Venki Avalur, and Vijay Dodd, Blendid is improving the consumer experience by offering safe, cost-effective, and personalized food on-demand, while also reducing complexities and costs for the operators. Blendid has raised more $20M to date from a mix of venture and crowdfunding investors and is currently raising its Series B investment round. Visit www.startengine.com/blendid for more information and to invest in the future of food service automation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information. Contact Details Erica Camilo 344130@email4pr.com Company Website http://www.blendid.com

February 28, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?

RazorPitch DarioHealth

Dexcom and Dario think alike when it comes to the elements of an effective solution: user engagement, health outcomes, and return on investment. Diabetics are likely to have more than one chronic condition, Dario’s engaging and highly rated multi-chronic condition platform leads to better clinical outcomes and delivers a measurable ROI. Dario’s platform leapfrogs Dexcom’s mission (slide 24) “Where the company is going: Type 2 Non-Insulin, Pre-Diabetes, Patient Monitoring, and Health & Wellness”. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions. Market overlooking global industry leaders: Sanofi, Aetna, and now Dexcom validating DarioHealth’s revolutionization in healthcare management of people with single or multi-chronic conditions through a user-centric platform. DarioHealth is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. Dario’s user-centric platform offers people continuous and customized care for health, disrupting the traditional, doctor centric, episodic approach to healthcare. Dario’s platform empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and improved health outcomes which result in a measurable ROI to payors. Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions. On March 1, 2022, Dario entered a multi-year $30 million-dollar strategic agreement with Sanofi U.S.(EURONEXT: SAN and NASDAQ: SNY ) designed to accelerate commercial adoption and drive the expansion of digital health solutions on the Dario platform. Sanofi selected Dario to leverage its broad suite of digital therapeutics and its ability to engage patients for favorable clinical and financial outcomes, as the solution of choice for its U.S. commercial clients. Strategic partnerships with Sanofi, Virgin Pulse, Solera and Alliant give Dario access to more than 10,000 employers and more than 50 health plans as potential clients for the platform. Dario’s preliminary results demonstrate successful B2C to B2B transformation. Total revenue for the year is expected to be $27.5 million compared to $20.5 million in 2021. Higher revenues on lower spend demonstrates that the strategy of moving from B2C to B2B sales channels has resulted in an overall significant improvement in the financial profile of the Company. The Company reduced its operating loss by more than 30% compared to the third quarter ended September 30, 2022, and by more than 50% compared to the fourth quarter of 2021. DarioHealth had $49.3 million of cash and cash equivalents at the end of 2022. Dexcom’s global leadership position in CGM delivers solid results On February 9 th, 2023, Dexcom Reported 2022 Financial Results. Full year revenue grew 19% to $2.91 billion. GAAP operating income totaled $391.2 million or 13.4% of revenue. Dexcom delivered record new customer starts, drove multiple new product launches, and significantly expanded access to Dexcom CGM around the world. As of December 31, 2022, Dexcom held $2.46 billion in cash or equivalents. Sanofi delivers strong sales performance and double digit EPS growth On February 3 rd, 2023, Sanofi (EURONEXT: SAN and NASDAQ: SNY) reported full year 2022 results highlighting 7% sales growth to 43 Billion Euro and 17% EPS growth. Free cash flow from operations totaled 8.5 Billion Euro. Sanofi is an innovative global healthcare company chasing miracles of science to improve people’s lives. The Company provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, sustainably and socially responsible. RCA Financial Partners Inc. ("RCA Partners" or "we" is a consulting and advisory firm to small public and pre-IPO data resource innovators at the critical inflection point where proven technology requires prudent financing for success. We help our clients connect with well informed investors. To learn more about RCA Financial Partners and its data resource innovators, visit www.rcafinancialpartners.com. Disclaimers: This article contains sponsored content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. RazorPitch authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. RazorPitch has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website. This summary report was prepared by RCA Financial Partners and distributed by RazorPitch. RCA Financial Partners is not a securities broker-dealer, an investment adviser, or a bank, and, accordingly, this report is not subject to FINRA or SEC rules regarding broker-dealer securities research, nor to the regulations to which investment advisers or banks are subject, including regulations regarding independence of written communications. RCA has been retained and compensated by the subject company of this report. This report does not constitute, and should not be construed as an independent analysis of the subject company, or as an offer to buy or sell, or a solicitation of an offer to buy or sell any security. This report is published without regard to the specific needs of any person, and it does not take into account the particular financial situation or needs of any individual. Readers should seek professional financial advice, including tax advice, before taking any investment decision. This report is based on information that we believe to be reliable, but RCA Financial Partners does not make any express or implied representation or warranty as to the completeness, reliability, or accuracy of information contained in this report, or of information used to create this report. Further important disclosures and disclaimers are available at: www.rcafinancialpartners.com/about-us/legal-disclaimer/ Contact Details Mark McKelvie +1 585-301-7700 Company Website http://razorpitch.com

February 28, 2023 05:00 AM Eastern Standard Time

Article thumbnail News Release

CleverTap’s Fintech Benchmark Report: Only 1 in 5 users that install fintech apps sign up within week one

CleverTap

CleverTap, the modern integrated retention cloud, released its Industry Benchmark Report for Fintech Apps 2022. As fintech apps continue to grow more popular, the number of players vying for market share has increased. This has subsequently reduced customer retention and “stickiness” for any one brand. Therefore, today more than ever, it is crucial that fintech companies find ways to drive customer “stickiness” by engaging users in effective ways that eventually drive transactions and fuel growth. The report reflects data collected from Asia-Pacific, Europe, India, Latin America, Middle-East, and North America. The report gives marketers a truly holistic view of key metrics within the fintech app landscape.It also spans a wide variety of fintech apps, including, but not limited to, mobile payment apps, cryptocurrency, and block chain services, along with banking and insurance among others. These insights will not only serve as a helpful starting point for developing successful engagement strategies, but also assist in understanding how an app fares in comparison to global averages. Some of the key metrics in the report include: Install to sign-up rate: Only 1 in 5 users that install fintech apps (21%) end up signing up within the first week. Average time to sign-up: 70% of the users that sign-up, do so within 75 seconds of launching the app for the first time. Sign-up to conversion rate: 95% of newly signed-up users make at least one financial transaction in the first month. Average time to convert: 76% of newly signed-up users move from onboarding to deeper-in-the-funnel engagement within an average of 7 days. Session frequency: On average, fintech app users launch their app around 11 times a month. Average repeat transaction rate for new users: 15% of newly signed-up users complete more than one transaction in the first week. Average click-through rate for push notifications: On average, 9% of Android users and 6% of iOS users will click on and interact with push notifications. Average click-through rate for in-app notifications: The click-through rate for in-app notifications is 24%, that’s about 3 times more than that of push notifications. Average email open rate: 34% users open emails sent by fintech companies Average Stickiness Quotient: Fintech apps enjoy a stickiness quotient of 22%, that indicates nearly one-quarter of MAUs consistently return to their fintech apps “The fintech industry has seen exponential growth in the last few years. Given the relentless competition within the space, fintech platforms need to step up their Omnichannel engagement efforts to better retain customers,” said Jacob Joseph, VP-Data Science, CleverTap. “The benchmark metrics laid out in our report provide a great starting point for growth marketers looking to develop effective marketing strategies. They will be able to compare numbers against global averages and pinpoint which aspects they are excelling at and which areas could use some attention or innovation.” 95% of new fintech users complete a monetary transaction in the first month. This shows that while users see value in fintech apps, it’s important to adopt customized user engagement strategies to boost retention on the platform. Today there is a real need for fintech brands to bake-in effective marketing strategies within their apps. Users will remain responsive as long as the experience is engaging and seamless. The benchmark report helps fintech apps understand how to build successful mobile communication campaigns, and also allows growth marketers to discover areas that require greater focus. The report can be downloaded here. About CleverTap CleverTap is the World's #1 Retention Cloud that helps app-first brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ - the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Gojek, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa Johns, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

February 27, 2023 02:51 PM Eastern Standard Time

Article thumbnail News Release

Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing

Todos Medical Ltd.

Todos Medical CEO Gerald Commissiong joined Proactive's Natalie Stoberman to discuss the validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing. Commissiong also talked about how this new validation plan intertwines with this week's company update and the growth across Todos Medical's projects and subsidiary 3CL Pharma. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 27, 2023 01:15 PM Eastern Standard Time

Video
Article thumbnail News Release

BioLargo subsidiary Clyra Medical Technologies adds medical industry veterans to board of directors

BioLargo Inc

BioLargo CEO Dennis Calvert joined Proactive's Natalie Stoberman to share more details of the addition of Nicholas Valeriani and Linda Park to the board of directors of subsidiary Clyra Medical Technologies. BioLargo noted that Valeriani has decades of executive experience in the medical device industry. He spent 34 years at Johnson & Johnson, where he led several corporate functions and was a member of its executive committee. Park is a trusted executive and legal professional with a proven track record of supporting and advising public companies at the corporate board and executive level at billion-dollar corporations. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 27, 2023 01:09 PM Eastern Standard Time

Video
Article thumbnail News Release

Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joins Proactive's Natalie Stoberman to discuss the positive safety review for its Phase 2 clinical trial for its SBI-100 Ophthalmic Emulsion. Dhillon said the trial's safety review committee has recommended that the trial continue without modification. Now, the company is preparing for Phase 3 recruitment for the third cohort of eight participants with dosing planned for March. Contact Details Proactive Investors US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 24, 2023 11:55 AM Eastern Standard Time

Video
Article thumbnail News Release

Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to announce the acquisition of Healion Bio, including its entire portfolio of next-generation antiviral technology assets. Lederman said the acquired portfolio of infectious disease assets includes a class of potential broad-spectrum antiviral agents, TNX-3900, with a host-directed mechanism. Tonix said it plans to develop the TNX-3900 series of molecules as oral antivirals, either as monotherapy or in combination with other antivirals. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 24, 2023 11:39 AM Eastern Standard Time

Video
Article thumbnail News Release

Pressure BioSciences’ Breakthrough UltraShear Nanoemulsion Processing Could Help Revolutionize The Edible Cannabis Industry

Pressure BioSciences Inc.

By Rachael Green, Benzinga Earlier this month, Pressure BioSciences, Inc. (OTCQB: PBIO) announced potentially ground-breaking results from a consumer focus group testing a THC oral spray developed using the company’s innovative UltraShear™ Technology nanoemulsification platform. The oral spray boasted strong potency and extremely fast absorption that could put it on track to become a best-in-class cannabis product in terms of speed to effects, stability, and bioavailability. The THC oral spray tested in this consumer focus group is being developed in partnership with California-based cannabis manufacturer, Crème De Canna. The news comes on the heels of the company’s December announcement of its first commercial shipment of a CBD oral spray manufactured with the same UltraShear technology. The $75,000 shipment to Safer Medical of Montana is the first of many shipments the company expects to make to distributors of CBD products throughout the U.S. during 2023. In recent press releases, PBIO has stated that CBD products manufactured using its patented UltraShear platform could potentially yield many millions in revenue before the end of its 2023 fiscal year. Slow And Inconsistent THC Absorption Remains A Key Challenge for Cannabis Manufacturers Because cannabinoids, like the well-known THC and CBD, are oil-soluble rather than water-soluble, the human body struggles to absorb them efficiently. As a consequence, much of the active ingredient in edible cannabis products is absorbed slowly, intermittently, or hardly at all. In one review of cannabis research, only 4% to 12% of THC was absorbed by the body when taken orally. Not only does that mean that the majority of the THC in an edible ends up getting wasted, but the variation in bioavailability between 4% and 12% is highly significant. A consumer eating the same edible product from the same manufacturer with the same dose might absorb just 4% one day but 12% the next day, leading to very different results. This makes it incredibly difficult for manufacturers to achieve precise dosing and effects in their edibles. It also increases production costs since they often need to include more than the minimum effective dose to compensate for the fact that most of the active ingredients won’t be absorbed. In addition to inefficient and inconsistent cannabinoid absorption, another challenge in the edible cannabis industry is absorption time. It is estimated to take anywhere from 30 minutes to two hours from the time a consumer ingests an edible to the time they start to feel its first effects, and then up to four hours to achieve peak effects. “Impatient consumers may repeatedly consume their edibles, only to be unhappily overdosed shortly thereafter,” explained PBI’s Director of Sales and Marketing, John Hollister in a statement on the consumer testing results. For patients using cannabis as a treatment for pain, anxiety, or depression, that delayed response also means edible cannabis is often unable to provide the instant relief they need. While smoking or vaping comes with a higher bioavailability of around 30% and a faster response time of seconds or minutes, the respiratory health consequences make it a less-than-ideal option, especially for regular use. PBI’s UltraShear Nanoemulsion Technology Could Be A Breakthrough In Achieving Precision Dosing for THC, CBD, and Other Products Consumers in the focus group reported that the first effects could be felt less than 10 minutes after initially using the innovative UltraShear processed THC oral spray, with many reporting noticeable effects within 1-5 minutes. Peak effects were achieved between 15-60 minutes after taking the dose. The results of this initial focus group could be a game-changer for an industry that’s been struggling with the challenges around consistent dosing and effective non-inhalation absorption. “This testing has provided dramatic consumer-level validation in the cannabis market for our UltraShear nanoemulsion capabilities and for its expected market-changing impact,” said Mr. Hollister. The UltraShear technology used to make the oral spray is PBI’s patented pressure-based platform that’s capable of creating what the company describes as the “best-in-class” nanoemulsions worldwide. In the cannabis nanoemulsion, the oil drops containing the CBD or THC molecules are sheared down to a nanosize so small that they are effectively water-soluble. This makes for a significantly more easily absorbed product that can be more precisely and accurately dosed. For consumers, that means more immediate and consistent effects every time they use an UltraShear processed oral spray or other mechanisms for ingestion. For manufacturers, that improved bioavailability means smaller amounts of THC or CBD are required to achieve an effective dose since the less active ingredient is getting wasted - thus saving the manufacturer money. “It provides an easy-to-use, reliable, and healthy alternative dosing format, with nearly immediate onset and a consistent experience associated with inhaling, but without the respiratory health risks associated with smoking and vaping. It also eliminates the frustrating delayed effects, imprecision, and frequent overdosing associated with edibles,” said Crème De Canna President, Jonathan Kolodinski. This article was originally published on Benzinga here. Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ken Micciche: Director, Business Development kmicciche@pressurebiosciences.com Company Website https://www.pressurebiosciences.com/

February 24, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

Freedom Holdings Gives Insight of the New Corporate Focus

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce the new management’s long-term goal in the cannabis arena which completes our plan to re-structuring the company with a productive reorganization in the Cannabis arena. With MEDcann, Inc. as our new majority owned shareholder, the Company is a Medical Cannabis Company focusing on Beverage manufacturing under 420 Beverages which is partners with a 420 - 215 licensed company called the Medical Cannabis, Inc. a subsidiary of MedCann. We are focusing on Research, in medical beverages, overseeing product manufacturing and sales. Our divisions in the cannabis industry, along with their associated products in the medical and health industries plans to Grow, Cultivate, Research and Manufacture CBD and THC beer and soft drinks in the medical marijuana industry with products that help a variety of maladies. Our intent is to conduct and pass Clinical Trials pursuant to offer the credibility needed so we can obtain FDA and Patient Recognition. Since there are over 1000 chemicals in each strain of cannabis it maybe next to impossible to get approval, but we plan to set a precedence and mark the new beginning of history by opening the doors to recognition of the potential future for patient curiosity and satisfaction in treating cancer and the associated pain that accompanies the devastating condition. FDA approval will afford us the ability to pursue Insurance company acceptable to support patient access to our VCO (Visita Care Oil) a remake of the RSO (Rick Simpson Oil). RSO is a cannabis concentrate used for many different medical benefits, including relieving cancer symptoms. Press Release Contact: John Vivian CEO Freedom Holdings, Inc. 260-490-9990 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. +1 260-490-9990

February 24, 2023 08:30 AM Eastern Standard Time

1 ... 129130131132133 ... 248
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.